ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
High-Density E. Coli Cultivation Arrays for Combinatorial Drug Testing With Subsequent Lipid Profiling by MALDI-MS.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The increasing resistance of bacteria to current drugs underscores the urgent need for new antibiotics. Combination therapies offer an alternative strategy by enhancing efficacy and delaying resistance, with synergies assessed in checkerboard assays using systematically varied drug concentrations. Here, we introduce a miniaturized checkerboard assay for high-throughput combinatorial antibiotic testing against E. coli. Our platform reduces sample volume significantly, achieves high sample densities of 20832 droplets per microscopy slide, and allows generation of checkerboard arrays in under 25 min prior to incubation and analysis. We established the platform by comparing E. coli growth across different culture volumes and performed assays to determine the minimum inhibitory concentration (MIC) for various drugs. Further, we replicated the synergistic effect of amoxicillin/clavulanate against an amoxicillin-resistant strain. Testing various antibiotic combinations allowed us to determine fractional inhibitory concentration indices (FICI) of up to 1.86 ± 0.42, suggesting indifferent effects with a tendency towards antagonism. Lipidomic profiling of E. coli revealed the characteristic lipid composition of primarily phosphatidylethanolamines (PE) and phosphatidylglycerol (PG). We identified PE32:0 that showed enhanced signal intensities at the MIC region, hinting at stress-induced lipid changes. Our platform holds promise for exploring combinatorial drug effects across cell types, with unique capabilities for simultaneous cell monitoring and MALDI-MS analysis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.